electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Rhea-AI Summary
electroCore (Nasdaq: ECOR) announced that company management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.
Management will host one-on-one meetings throughout the day. Investors seeking a meeting should contact their Canaccord Genuity sales representative or email electroCore Investor Relations at ecor@fnkir.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ECOR gained 1.29%, reflecting a mild positive market reaction. This price movement added approximately $646K to the company's valuation, bringing the market cap to $51M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.
Management will host one-on-one meetings throughout the day.
Investors who wish to request a meeting should contact their sales representative at Canaccord Genuity or reach out to electroCore Investor Relations at ecor@fnkir.com.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
When will electroCore (ECOR) participate at the Canaccord Genuity forum?
Where is the Canaccord Genuity MedTech forum where ECOR will appear?
How can investors request a one-on-one meeting with electroCore (ECOR) at the November 20, 2025 forum?
Will electroCore (ECOR) management hold multiple investor meetings at the event on November 20, 2025?
Who should institutional investors contact to arrange meetings with ECOR at the Canaccord forum?
